Overview

Psilocybin rTMS for Treatment Resistant Depression

Status:
Not yet recruiting
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas at Austin
Treatments:
Psilocybin